Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Acknowledgement of manuscript reviewers 2014.

Fisman E, Tenenbaum A.

Cardiovasc Diabetol. 2015 Apr 15;14:34. doi: 10.1186/s12933-015-0186-3.

2.

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Tenenbaum A, Klempfner R, Fisman EZ.

Cardiovasc Diabetol. 2014 Dec 4;13(1):159. doi: 10.1186/s12933-014-0159-y.

3.

Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: Insights from the ACS Israeli Survey (ACSIS) 2000-2010.

Klempfner R, Elis A, Matezky S, Keren G, Roth A, Finkelstein A, Banai S, Goldenberg I, Fisman EZ, Tenenbaum A, Arbel Y.

Int J Cardiol. 2015 Jan 20;179:546-51. doi: 10.1016/j.ijcard.2014.10.116. Epub 2014 Oct 22.

PMID:
25466560
4.

Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2014 Jun 23;13:103. doi: 10.1186/1475-2840-13-103. Review.

5.

Authors' response.

Fisman EZ, Tenenbaum A.

Cardiol J. 2014;21(2):210. doi: 10.5603/CJ.2014.0033. No abstract available.

PMID:
24752953
6.

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns.

Shemesh J, Tenenbaum A, Fisman EZ, Koren-Morag N, Grossman E.

Cardiovasc Diabetol. 2013 Nov 5;12:161. doi: 10.1186/1475-2840-12-161.

7.

Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome.

Klempfner R, Goldenberg I, Fisman EZ, Matetzky S, Amit U, Shemesh J, Tenenbaum A.

Am J Cardiol. 2014 Jan 1;113(1):12-6. doi: 10.1016/j.amjcard.2013.08.033. Epub 2013 Oct 2.

PMID:
24157192
8.

Bezafibrate treatment is associated with a reduced rate of re-hospitalization in smokers after acute coronary syndrome.

Klempfner R, Goldenberg I, Fisman EZ, Amit U, Haitovich A, Matetzky S, Medvedofsky D, Shemesh J, Tenenbaum A.

Cardiol J. 2014;21(4):364-9. doi: 10.5603/CJ.a2013.0127. Epub 2013 Oct 21.

PMID:
24142677
9.

Optimal revascularization in diabetes after the FREEDOM trial: were the controversies finally settled?

Tenenbaum A, Fisman EZ.

Cardiol J. 2013;20(4):331-6. doi: 10.5603/CJ.2013.0090. Review.

10.

The metabolic syndrome entanglement: Cutting the Gordian knot.

Fisman EZ, Tenenbaum A.

Cardiol J. 2014;21(1):1-5. doi: 10.5603/CJ.a2013.0054. Epub 2013 May 15.

PMID:
23677720
11.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

12.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

13.

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.

Klempfner R, Leor J, Tenenbaum A, Fisman EZ, Goldenberg I.

Cardiovasc Diabetol. 2012 Jun 6;11:60. doi: 10.1186/1475-2840-11-60.

14.

Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.

Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I.

PLoS One. 2012;7(4):e35298. doi: 10.1371/journal.pone.0035298. Epub 2012 Apr 16.

15.

The doubtful association between blood lipid changes and progression of coronary calcification.

Tenenbaum A, Fisman EZ, Shemesh J, Motro M.

Int J Cardiol. 2011 Dec 1;153(2):224-5. doi: 10.1016/j.ijcard.2011.09.058. Epub 2011 Oct 11. No abstract available.

PMID:
21996414
16.

Fibrate use in the United States and Canada.

Tenenbaum A, Fisman EZ.

JAMA. 2011 Jul 13;306(2):157; author reply 158-9. doi: 10.1001/jama.2011.945. No abstract available.

PMID:
21750290
17.

"The metabolic syndrome... is dead": these reports are an exaggeration.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2011 Jan 27;10:11. doi: 10.1186/1475-2840-10-11.

18.

The ubiquitous interleukin-6: a time for reappraisal.

Fisman EZ, Tenenbaum A.

Cardiovasc Diabetol. 2010 Oct 11;9:62. doi: 10.1186/1475-2840-9-62.

19.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk